NEW YORK (GenomeWeb News) – Mayo Clinic today announced it has licensed patent rights from Qiagen that will allow Mayo Medical Laboratories to offer a test for M. tuberculosis complex speciation.
Financial and other terms of the deal were not disclosed.
In an e-mail, Nancy Wengenack, associate professor of Laboratory Medicine and Pathology at the Mayo Medical School College of Medicine, said that the new test will be PCR-based and use fluorescence resonance energy transfer hybridization probes for detection.
In a statement, Mayo said that the Qiagen-based test will expand its current offering of tuberculosis testing, which includes M. tuberculosis complex culture, molecular identification, and drug susceptibility testing.
Mayo also offers PCR-based testing for M. tuberculosis complex directly from specimens and molecular detection of drug-resistance markers for the drugs isoniazid and pyrazinamide.